Compare BIO-TECHNE Corp (TECH) vs Veritone Inc (VERI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Veritone Inc — how do they compare? BIO-TECHNE Corp trades at $72.39 (market cap $11.34B), while Veritone Inc trades at $0.87 (market cap $91.43M). The key difference: BIO-TECHNE Corp is far larger — about 124× Veritone Inc's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Veritone Inc pays none. Which is the better fit depends on your goals.
| TECH | VERI | |
|---|---|---|
Market Cap | $11.34B | $91.43M |
Sector | Health | Technology |
52-Week High | $72.48 | $8.39 |
52-Week Low | $43.31 | $0.79 |
Enterprise Value | $11.36B | $126.82M |
Dividend Yield | 0.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.31, down 0.17% on the day, with a neutral technical signal and mixed earnings history. The stock is near the consensus price target of $71.86, with a pending acquisition by Merck KGaA at $73.00 per share. Recent Q4 2026 revenue beat estimates, but net income margin compression from 25.09% in 2023 to 14.96% in 2026 highlights profitability challenges. Operating cash flow remains stable around $290M, supporting dividend payments.
The outlook is balanced, with upside capped by the acquisition offer but supported by solid cash flow and analyst hold ratings. Risks include shareholder litigation and integration uncertainties post-acquisition. Earnings growth in diagnostics and spatial biology segments is a key catalyst, though high P/E of 62.33 suggests elevated expectations.
Veritone (VERI) trades at $0.9155, up 0.99% on the day, amid a bearish technical signal with mixed oscillators. The company reported Q2 2026 revenue of $24.3 million, up 20% sequentially, but continues to post significant losses, with a net income margin of -117.54% in 2025. Recent news highlights a securities class action investigation announced by Kaskela Law on August 20, 2026, adding legal overhangs to operational challenges.
The outlook remains challenged by persistent unprofitability and negative cash flow from operations, offset by a balanced analyst consensus of 46% buy and 46% hold ratings. Key risks include ongoing legal scrutiny, high operating costs, and the need to achieve sustainable profitability to support the stock's valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Veritone Inc
Veritone is a leading provider of enterprise AI software and solutions, centered on its proprietary AI operating system, aiWARE™. The platform orchestrates a vast ecosystem of machine learning models to transform unstructured data—such as audio, video, and text—into actionable intelligence. Serving the media, entertainment, and public sectors, Veritone is a critical infrastructure partner for organizations looking to monetize data archives and operationalize AI at scale.
Read more on VERI →
